The Cost and Public Health Burden of Invasive Meningococcal Disease Outbreaks: A Systematic Review

被引:23
|
作者
Anonychuk, Andrea [1 ,2 ,3 ]
Woo, Gloria [4 ]
Vyse, Andrew [1 ]
Demarteau, Nadia [1 ]
Tricco, Andrea C. [5 ]
机构
[1] GlaxoSmithKline Vaccines, Wavre, Belgium
[2] Abbott Labs, Div Diagnost, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Div Diagnost, Mississauga, ON L5N 3R3, Canada
[4] Univ Toronto, Toronto Hlth Econ & Technol Assessment Collaborat, Toronto, ON, Canada
[5] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada
关键词
NEISSERIA-MENINGITIDIS; CONJUGATE VACCINE; UNITED-STATES; SEROGROUP; IMMUNOGENICITY; POLYSACCHARIDE; SAFETY; W-135; INFECTION; ENGLAND;
D O I
10.1007/s40273-013-0057-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background Invasive meningococcal disease (IMD) is a serious disease with a rapid onset, high mortality rate, and risk of long-term complications. Numerous reports in the literature conclude that IMD outbreaks are associated with substantial costs to society and significant burden on communities due to the cost associated with the prevention of secondary cases. Objective To systematically review the literature on the costs and public health burden associated with IMD outbreaks. Methods Studies were primarily identified through searching MEDLINE and EMBASE. Reports were included if they provided cost data related to the containment of an IMD outbreak after 1990 and were written in English, French, or Spanish. Costs were converted to 2010 United States dollars. Outbreaks were categorized by low-income countries (LIC) and high-income countries (HIC) based on gross domestic product per capita. Outbreak containment strategies were classified as small (e.g., targeting members of the school/institution where the outbreak occurred) or large (e.g., targeting everyone in the community). Results Sixteen articles reporting data on 93 IMD outbreaks fulfilled the eligibility criteria and were included. The majority of outbreaks occurred in HIC. Five studies reported the use of small containment strategies including targeted vaccination and chemoprophylaxis, all occurring in HIC. The average cost per small containment strategy was $299,641 and the average cost per IMD case was $41,857. Eight studies reported large containment strategies involving widespread vaccination targeting a specific age group or community. For HIC, the average cost per large containment strategy was $579,851 and the average cost per IMD case was $55,755. In LIC, the average cost per large containment strategy was $3,407,590 and the average cost per IMD case was $2,222. Conclusion IMD outbreaks were associated with substantial costs. We found that although there were numerous reports on IMD outbreaks, data on containment costs were very limited. More research in this area is warranted.
引用
收藏
页码:563 / 576
页数:14
相关论文
共 50 条
  • [31] The burden of invasive meningococcal disease in the Netherlands, 2011-2020
    Middeldorp, Marit
    Steens, Anneke
    Lagerweij, Giske
    van Sorge, Nina M.
    Freudenburg-de Graaf, Wieke Freudenburg-de
    Sanders, Elisabeth A. M.
    de Melker, Hester E.
    Knol, Mirjam J.
    VACCINE, 2023, 41 (16) : 2664 - 2670
  • [32] THE COST OF ILLNESS FOR INVASIVE MENINGOCOCCAL B DISEASE IN GERMANY
    Scholz, S.
    Meszaros, K.
    Fassbender, R. M.
    Welte, R.
    Greiner, W.
    Koerber, F.
    VALUE IN HEALTH, 2017, 20 (09) : A785 - A785
  • [33] The global burden of hepatitis E outbreaks: a systematic review
    Hakim, Mohamad S.
    Wang, Wenshi
    Bramer, Wichor M.
    Geng, Jiawei
    Huang, Fen
    de Man, Robert A.
    Peppelenbosch, Maikel P.
    Pan, Qiuwei
    LIVER INTERNATIONAL, 2017, 37 (01) : 19 - 31
  • [34] Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region
    Alp Giray Dogu
    Anouk M. Oordt-Speets
    Femke van Kessel-de Bruijn
    Mehmet Ceyhan
    Amine Amiche
    BMC Infectious Diseases, 21
  • [35] Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers
    Olbrich, Kerstin J.
    Mueller, Dirk
    Schumacher, Sarah
    Beck, Ekkehard
    Meszaros, Kinga
    Koerber, Florian
    INFECTIOUS DISEASES AND THERAPY, 2018, 7 (04) : 421 - 438
  • [36] Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers
    Kerstin J. Olbrich
    Dirk Müller
    Sarah Schumacher
    Ekkehard Beck
    Kinga Meszaros
    Florian Koerber
    Infectious Diseases and Therapy, 2018, 7 : 421 - 438
  • [37] Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review
    Begum, Shahina
    Herrera-Restrepo, Oscar
    Rolland, Catherine
    Purushotham, Sneha
    Andani, Anar
    Shah, Hiral
    Kocaata, Zeki
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [38] Policies for public health management of meningococcal disease
    Begg, N
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 1999, 53 (09) : 516 - 516
  • [39] A SYSTEMATIC REVIEW OF THE COST BURDEN OF GOUT
    Neves, C.
    Shields, G. E.
    Beard, S.
    VALUE IN HEALTH, 2015, 18 (07) : A656 - A656
  • [40] A TARGETED REVIEW OF EVIDENCE ON INVASIVE MENINGOCOCCAL DISEASE BURDEN, PREVENTION CHALLENGES, AND OPPORTUNITIES FOR IMPROVEMENT IN THE UNITED STATES
    Herrera-Restrepo, Oscar
    Shah, Hiral
    Clements, Diana
    Andani, Anar
    Kocaata, Zeki
    JOURNAL OF ADOLESCENT HEALTH, 2025, 76 (03)